Western pharmaceutical companies are no longer seeking cheap 'me-too' assets in China. Instead, they are paying premium prices for genuinely innovative drugs, as evidenced by a 10x increase in deal size over five years and a surge in patent filings from the region.

The perception of China's biotech industry as purely 'copycat' is outdated. Chinese firms are now developing novel assets, like PD-1 VEGF bispecifics, that represent a level of investment risk that Western VCs and pharma might avoid, signaling a clear shift towards original, high-impact innovation.

When prioritizing pipelines, biotechs must consider commercial viability, not just science. With China's ecosystem specializing in fast-follow "Me Too" drugs, such assets are becoming commoditized. To secure funding and premium exits, companies must focus on truly differentiated "first-in-class" or "best-in-class" programs.

While the U.S. excels at high-risk 'zero to one' innovation, Chinese biotechs are mastering 'me-better' optimization. This is where significant commercial value is captured, as opposed to the initial, riskier discovery phase, posing a new competitive threat.

To compete with China's rapid 'me-better' development, U.S. innovators should proactively partner with Chinese firms to create improved versions of their own drugs. This self-cannibalization strategy is necessary to stay ahead before competitors do it for them.

Acknowledging that China's development speed for known targets is "unparalleled," the CEO's strategy is not to match it. Instead, the competitive edge comes from the innovative front-end: discovering novel target pairings from a proprietary platform that others cannot.

Faced with China's superior speed and cost in executing known science, the U.S. biotech industry cannot compete by simply iterating faster. Its strategic advantage lies in

China's pharmaceutical industry is rapidly shifting from manufacturing generics to creating novel drugs. It already accounts for 30% of new innovative drugs globally, up from virtually zero 15 years ago. The prediction is that it will reach 40% by 2030, becoming the world's number one source for medical innovation.

The increasing innovation and speed from China puts pressure on the U.S. biotech ecosystem. To remain competitive, the U.S. must focus on collaboration and address its own systemic issues, such as slow trial execution and the high cost of getting a drug to the IND stage.